RecruitingNCT07147465

Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for Oncology Patients

Studying Rare neoplastic disease

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Assistance Publique - Hôpitaux de Paris
Principal Investigator: Isabelle DURAND-ZALESKI, Professor
Greater Paris University Hospitals
Enrollment: 3149 enrolled
Eligibility: All sexes
Timeline: 2025 – 2026

Study locations (3)

Centre Leon Berard, Lyon, France
APHP Hôtel Dieu URC Economie de la sante /URC ECO, Paris, France
HOPITAL AP-HP Cochin, Paris, France

Collaborators

AuraGen Aesthetics LLC · Centre Leon Berard · Laboratoire SeqOIA · PLAN FRANCE MÉDECINE GÉNOMIQUE 2025

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07147465 on ClinicalTrials.gov

Other trials for Rare neoplastic disease

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE2NCT04423185
PLATFORM Study of Precision Medicine for Rare Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

See all trials for Rare neoplastic disease →

← Back to all trials